Search results for "Ca15.3"

showing 10 items of 22 documents

A headlight on liquid biopsies: a challenging tool for breast cancer management

2016

Breast cancer is the most frequent carcinoma and second most common cause of cancer-related mortality in postmenopausal women. The acquisition of somatic mutations represents the main mechanism through which cancer cells overcome physiological cellular signaling pathways (e.g., PI3K/Akt/mTOR, PTEN, TP53). To date, diagnosis and metastasis monitoring is mainly carried out through tissue biopsy and/or re-biopsy, a very invasive procedure limited only to certain locations and not always feasible in clinical practice. In order to improve disease monitoring over time and to avoid painful procedure such as tissue biopsy, liquid biopsy may represent a new precious tool. Indeed, it represents a bas…

0301 basic medicineCA15-3OncologyCancer Researchmedicine.medical_specialtyPathologyBiopsyBreast NeoplasmsMetastasis03 medical and health sciencesBreast cancer0302 clinical medicineBreast cancerCirculating tumor cellInternal medicineBiopsyBiomarkers TumormedicineCarcinomaHumansPTENNeoplasm MetastasisLiquid biopsyBreast cancer; Circulating tumor cells; Circulating tumor DNA; CTCs; ctDNA; Liquid biopsy; Cancer ResearchCirculating tumor DNALiquid biopsybiologymedicine.diagnostic_testbusiness.industryCirculating tumor cellctDNADNA NeoplasmGeneral MedicineNeoplastic Cells Circulatingmedicine.diseaseCTC030104 developmental biology030220 oncology & carcinogenesisbiology.proteinFemalebusinessTumor Biology
researchProduct

Critical Roles of EGFR family members in breast cancer and breast cancer stem cells: Targets for therapy

2016

The roles of the epidermal growth factor receptor (EGFR) signaling pathway in various cancers including breast, bladder, brain, colorectal, esophageal, gastric, head and neck, hepatocellular, lung, neuroblastoma, ovarian, pancreatic, prostate, renal and other cancers have been keenly investigated since the 1980's. While the receptors and many downstream signaling molecules have been identified and characterized, there is still much to learn about this pathway and how its deregulation can lead to cancer and how it may be differentially regulated in various cell types. Multiple inhibitors to EGFR family members have been developed and many are in clinical use. Current research often focuses o…

0301 basic medicineCA15-3OncologyEGFR HER2 mIRs Cancer Stem Cells Drug Resistance Metastasismedicine.medical_specialtyEGFRDrug ResistancemIRCancer Stem CellBreast NeoplasmsNOMetastasisMetastasis03 medical and health sciences0302 clinical medicineBreast cancerCancer stem cellInternal medicineCancer Stem CellsHER2Drug DiscoverymicroRNAmedicineCancer Stem Cells; Drug Resistance; EGFR; HER2; Metastasis; mIRs; Pharmacology; Drug Discovery3003 Pharmaceutical ScienceAnimalsHumansEpidermal growth factor receptorPharmacologyCancer Stem Cells; Drug Resistance; EGFR; HER2; Metastasis; mIRsmIRsbiologybusiness.industryEGFR HER2 mIRs Cancer Stem Cells Drug Resistance Metastasis.Drug Discovery3003 Pharmaceutical ScienceCancermedicine.disease3. Good healthErbB Receptors030104 developmental biology030220 oncology & carcinogenesisbiology.proteinNeoplastic Stem CellsFemaleStem cellbusinessSignal Transduction
researchProduct

<p>Nab-paclitaxel in pretreated metastatic breast cancer: evaluation of activity, safety, and quality of life</p>

2019

Objective Metastatic breast cancer (MBC) is an incurable disease; the treatment of this disease prolongs survival, improving the quality of life (QoL) with a balance between efficacy and toxicity of the treatment. In recent years, treatment with nab-paclitaxel has improved the already known antitumor activity of conventional paclitaxel, in terms of increased efficacy and better tolerability. The aim of this study was to evaluate nab-paclitaxel in Italian patients with MBC. Methods We conducted a retrospective analysis of 90 patients with histologically confirmed diagnosis of MBC. To evaluate the efficacy of nab-paclitaxel, overall survival (OS), progression-free survival (PFS), and overall …

0301 basic medicineOncologyCA15-3medicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentDiseasemedicine.diseaseMetastatic breast cancer03 medical and health scienceschemistry.chemical_compound030104 developmental biology0302 clinical medicineOncologyQuality of lifePaclitaxelchemistryTolerability030220 oncology & carcinogenesisInternal medicineToxicitymedicinePharmacology (medical)businessOncoTargets and Therapy
researchProduct

Biological parameters in breast cancer.

1996

AdultAged 80 and overCA15-3Oncologymedicine.medical_specialtyPloidiesbusiness.industryGeneral NeuroscienceBreast NeoplasmsDNA NeoplasmMiddle AgedPrognosismedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologyS PhaseBreast cancerHistory and Philosophy of ScienceEvaluation Studies as TopicInternal medicinemedicineHumansFemalebusinessAged
researchProduct

Associations between Notch-2, Akt-1 and HER2/neu expression in invasive human breast cancer: a tissue microarray immunophenotypic analysis on 98 pati…

2007

<i>Objective:</i> We aimed to investigate the existence of associations between well-established and newly recognized biological and phenotypic features of breast cancer involved in tumor progression and prognosis. <i>Methods:</i> Ninety-eight cases of invasive breast cancer were assessed for the immunohistochemical expression of estrogen and progesterone receptors, Ki-67, HER2, Akt-1, and Notch-2, using the tissue microarray technique. Data regarding tumor histotype, histological grade, tumor size and lymph node status were collected for each patient and included in the analysis. <i>Results:</i> Several significant associations between histological and/o…

AdultOncologyCA15-3medicine.medical_specialtybreast cancer immunophenotypic analysis Notch-2 Akt-1 HER2/neuReceptor ErbB-2Breast NeoplasmsSettore MED/08 - Anatomia PatologicaHER2/neuImmunophenotypingPathology and Forensic MedicineBreast cancerImmunophenotypingInternal medicineBiomarkers TumormedicineHumansReceptor Notch2Notch 2Molecular BiologyProtein kinase BAgedAged 80 and overTissue microarraybiologybusiness.industryCancerCell BiologyGeneral MedicineMiddle Agedmedicine.diseaseReceptors EstrogenTissue Array Analysisbiology.proteinFemaleReceptors ProgesteronebusinessProto-Oncogene Proteins c-akt
researchProduct

Correlation of serum and salivary CA15-3 levels in patients with breast cancer

2008

Objectives: The aim of this study was to assess the relationship between serum and saliva levels of cancer antigen (CA) 15-3 and to compare them between women with and without breast cancer. Study design: A case-control study was carried out on 61 women aged 28-69 years, including women with and without breast cancer (26 as part of the case study and 35 as part of the control group) conducted at the Emam Khomeini Hospital, Tehran University of Medical Sciences. CA15-3 levels were assayed in serum and unstimulated whole saliva by EIA. Unpaired t-test, one-way ANOVA and Pearson correlation were used as statistical analysis. Results: The salivary and serological levels of CA15-3 in the cancer …

CA15-3Adultmedicine.medical_specialtySalivaBreast NeoplasmsGastroenterologySerologyBreast cancerInternal medicinemedicineHumansStage (cooking)SalivaGeneral DentistryAgedbusiness.industryMucin-1Case-control studyCancerMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]EndocrinologyOtorhinolaryngologyCase-Control StudiesUNESCO::CIENCIAS MÉDICASSurgeryFemaleAnalysis of variancebusiness
researchProduct

Oral contraceptive use and salivary C-erbB-2, CEA and CA15-3 in healthy women: a case-control study.

2009

Objectives: Oral contraceptives (OCP) are highly effective, safe and widely used. Higher exposure to endogenous and exogenous estrogens is generally thought to increase the risk of breast cancer. Therefore, this study was conducted to determine if oral contraceptive use affected the expression of CA 15-3, CEA and C-erb B-2 in the saliva of healthy women. Study design: The participants consisted of 87 healthy women (43 controls and 44 using oral contraceptives) ranging in age from 20 to 54 years. The volunteers participated by giving one ? time stimulated whole saliva samples. Then the samples were analysed for CA 15-3, CEA and C-erb B-2 concentrations. Results: The student t-test was used t…

CA15-3Adultmedicine.medical_specialtySalivaReceptor ErbB-2PopulationPhysiologyYoung AdultBreast cancerMedicineEndocrine systemHumanseducationSalivaGeneral DentistryGynecologyeducation.field_of_studybusiness.industryMucin-1Case-control studyCancerMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCarcinoembryonic AntigenOtorhinolaryngologyCase-Control StudiesUNESCO::CIENCIAS MÉDICASSurgeryCancer biomarkersFemalebusinessContraceptives OralMedicina oral, patologia oral y cirugia bucal
researchProduct

CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis.

2014

SummaryCancer stem cells drive tumor formation and metastasis, but how they acquire metastatic traits is not well understood. Here, we show that all colorectal cancer stem cells (CR-CSCs) express CD44v6, which is required for their migration and generation of metastatic tumors. CD44v6 expression is low in primary tumors but demarcated clonogenic CR-CSC populations. Cytokines hepatocyte growth factor (HGF), osteopontin (OPN), and stromal-derived factor 1α (SDF-1), secreted from tumor associated cells, increase CD44v6 expression in CR-CSCs by activating the Wnt/β-catenin pathway, which promotes migration and metastasis. CD44v6− progenitor cells do not give rise to metastatic lesions but, when…

CA15-3Animals; Biomarkers Tumor; Bone Morphogenetic Proteins; Carcinogenesis; Colonic Neoplasms; Fibroblasts; Humans; Hyaluronan Receptors; Mice SCID; Neoplasm Metastasis; Neoplasm Proteins; Neoplastic Stem Cells; Phosphatidylinositol 3-Kinases; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Signal Transduction; Treatment Outcome; Wnt Proteins; Cellular Reprogramming; Molecular Medicine; Genetics; Cell BiologyCarcinogenesisWnt ProteinMice SCIDmedicine.disease_causeAnimals; Antigens CD44; Biomarkers Tumor; Bone Morphogenetic Proteins; Carcinogenesis; Colonic Neoplasms; Fibroblasts; Humans; Mice SCID; Neoplasm Metastasis; Neoplasm Proteins; Neoplastic Stem Cells; Phosphatidylinositol 3-Kinases; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Signal Transduction; Treatment Outcome; Wnt Proteins; Cellular ReprogrammingMetastasisMicePhosphatidylinositol 3-KinasesCD44Neoplasm MetastasisCarcinogenesiPhosphoinositide-3 Kinase InhibitorsColonic NeoplasmTumorbiologyProto-Oncogene Proteins c-metCellular ReprogrammingPrognosisAntigens CD44Neoplasm ProteinsNeoplasm MetastasiAnimals; Antigens CD44; Biomarkers Tumor; Bone Morphogenetic Proteins; Carcinogenesis; Colonic Neoplasms; Fibroblasts; Humans; Mice SCID; Neoplasm Metastasis; Neoplasm Proteins; Neoplastic Stem Cells; Phosphatidylinositol 3-Kinases; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Signal Transduction; Treatment Outcome; Wnt Proteins; Cellular Reprogramming; Cell Biology; Molecular Medicine; GeneticsHyaluronan ReceptorsTreatment OutcomeBone Morphogenetic ProteinsColonic NeoplasmsNeoplastic Stem CellsFibroblastMolecular MedicineHepatocyte growth factorStem cellHumanmedicine.drugSignal TransductionPrognosiProtein Kinase InhibitorSCIDNeoplasm ProteinCancer stem cellSettore MED/04 - PATOLOGIA GENERALEmedicineGeneticsBiomarkers TumorAnimalsHumansAntigensProgenitor cellProtein Kinase InhibitorsSettore MED/04 - Patologia GeneraleAnimalBone Morphogenetic Proteincancer metastasisCD44Cell BiologyFibroblastsmedicine.diseaseWnt ProteinsSettore MED/18 - Chirurgia GeneraleImmunologyCancer researchbiology.proteinNeoplastic Stem CellPhosphatidylinositol 3-KinaseCarcinogenesisBiomarkersCell stem cell
researchProduct

Difference in Ki67 and thymidylate synthase expression in primary tumour compared with metastatic nodes in breast cancer patients.

2005

Breast cancer is a heterogeneous disease, so therapeutic predictive biological markers need to be identified. To date an accurate evaluation of predictive markers is mainly done at the primary site; however, the main goal of adjuvant therapy for breast cancer is the control of micrometastases. The aim of this study is to assess as therapeutic and/or prognostic marker, the proliferation status of primary tumors and involved nodes as measured by Ki67 and thymidylate synthase (TS) expression, in 30 breast cancer node positive patients. TS is the main target of 5-fluorouracil (5-FU) activity, and its overexpression is one of the mechanisms of 5-FU drug resistance; however, in some studies its a…

CA15-3Antimetabolites AntineoplasticProliferation indexBreast NeoplasmsDiseaseDrug resistanceBiologySettore MED/08 - Anatomia PatologicaBiochemistryThymidylate synthaseGene Expression Regulation EnzymologicBreast cancerbreast cancerAntigens NeoplasmGeneticsmedicineAdjuvant therapyHumansNeoplasm MetastasisCell ProliferationGeneral MedicineThymidylate SynthaseCell cyclemedicine.diseasePrognosisGene Expression Regulation NeoplasticKi-67 AntigenmetastaseLymphatic MetastasisImmunologyCancer researchbiology.proteinMolecular MedicineFemaleFluorouracilKi67Nucleosides, nucleotidesnucleic acids
researchProduct

Expression of stress protein gp96, a tumor rejection antigen, in human colorectal cancer

2000

Preparations of stress protein gp96 from tumor cells are active as tumor vaccines by eliciting immune responses against mixtures of individual tumor peptide antigens which are complexed to gp96. Due to the individual antigenicity of tumors, a vaccine consisting of tumor-derived gp96 has to be prepared individually for each patient from autologous tumor tissue. So far, gp96 expression by human tumors has not been analyzed. Here, we report stable and mostly homogenous expression of gp96 by colorectal cancer, which was enhanced compared to surrounding tumor stroma in 70% to 80% of colorectal cancer specimens. Fewer non-metastatic than metastatic primary cancer specimens showed enhanced gp96 ex…

CA15-3Cancer ResearchColorectal cancerbusiness.industryTumor M2-PKMouse model of colorectal and intestinal cancermedicine.diseaseImmunohistochemistryNeoplasm ProteinsImmune systemOncologyAntigenCell cultureImmunologymedicineHumansCA19-9Colorectal NeoplasmsbusinessHT29 CellsHeat-Shock ProteinsInternational Journal of Cancer
researchProduct